JB
James B. Chung, M.D., Ph.D.
Executive Vice President, Chief Regulatory and Quality Officer
Intellia TherapeuticsTherapeutic Areas
Intellia Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| NTLA-2002 (lonvoguran ziclumeran) | Hereditary Angioedema (HAE) | Phase 3 |
| NTLA-2001 | ATTR Amyloidosis (Cardiomyopathy/Polyneuropathy) | Phase 3 |
| NTLA-3001 | Hereditary Alpha-1 Antitrypsin Deficiency (AATD) | Phase 1/2 |
| NTLA-2003 | Glycogen Storage Disease Type Ia (GSDIa) | Preclinical |
Leadership Team at Intellia Therapeutics
JM
John M. Leonard, M.D.
President and Chief Executive Officer
LS
Laura Sepp-Lorenzino, Ph.D.
Executive Vice President, Chief Scientific Officer
DC
David C. Lubner
Executive Vice President, Chief Financial and Business Officer
JD
Jennifer Doudna, Ph.D.
Co-Founder
AP
Andrew P. May, Ph.D.
Executive Vice President, Chief Corporate Strategy Officer